Stifel lowered the firm’s price target on ResMed (RMD) to $240 from $250 and keeps a Hold rating on the shares. After having gathered survey responses from 47 U.S. Sleep Specialists, the firm tells investors that its physician feedback highlights several future challenges for the CPAP market that likely emerge from the increasing prominence of GLP-1s. The overall takeaway from the checks is “one of caution,” adds the analyst, who notes the the firm’s FY27 EPS view is now the “Street-low.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RMD:
- ResMed upgraded to Buy from Neutral at Citi
- ResMed added to APAC Conviction List at Goldman Sachs
- ResMed Reports Robust Growth and Innovation in Earnings Call
- Apple, Intel little changed near noon following earnings: Morning Buzz
- Zillow initiated, Electronic Arts upgraded: Wall Street’s top analyst calls
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue